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Protein arginine (Arg) methylation serves an important functional role in eucaryotic cells, and
typically occurs in domains consisting of multiple Arg in close proximity. Localization of
methylarginine (MA) within Arg-rich domains poses a challenge for mass spectrometry
(MS)-based methods; the peptides are highly charged under electrospray ionization (ESI),
which limits the number of sequence-informative products produced by collision induced
dissociation (CID), and loss of the labile methylation moieties during CID precludes effective
fragmentation of the peptide backbone. Here the fragmentation behavior of Arg-rich peptides
was investigated comprehensively using electron-transfer dissociation (ETD) and CID for both
methylated and unmodified glycine-/Arg-rich peptides (GAR), derived from residues 679–
695 of human nucleolin, which contains methylation motifs that are widely-represented in
biological systems. ETD produced abundant information for sequencing and MA localization,
whereas CID failed to provide credible identification for any available charge state (z  2–4).
Nevertheless, CID produced characteristic neutral losses that can be employed to distinguish
among different types of MA, as suggested by previous works and confirmed here with
product ion scans of high accuracy/resolution by an LTQ/Orbitrap. To analyze MA-peptides
in relatively complex mixtures, a method was developed that employs nano-LC coupled to
alternating CID/ETD for peptide sequencing and MA localization/characterization, and an
Orbitrap for accurate precursor measurement and relative quantification of MA-peptide
stoichiometries. As proof of concept, GAR-peptides methylated in vitro by protein arginine
N-methyltransferases PRMT1 and PRMT7 were analyzed. It was observed that PRMT1
generated a number of monomethylated (MMA) and asymmetric-dimethylated peptides,
while PRMT7 produced predominantly MMA peptides and some symmetric-dimethylated
peptides. This approach and the results may advance understanding of the actions of PRMTs
and the functional significance of Arg methylation patterns. (J Am Soc Mass Spectrom 2009,
20, 507–519) © 2009 American Society for Mass SpectrometryProtein arginine (Arg) methylations are prevalentin eucaryotes, and represent an important class ofpost-translational modifications (PTM) that can
alter essential biological processes such as signal trans-
duction, cellular proliferation, transcriptional process-
ing, protein–protein interactions, and splicing of mRNA
[1–3]. Protein Arg-methylation is also associated with
numerous diseases such as HIV, cancer, metabolic
disorders, and neurodevelopmental disorders [4–12].
Methylarginines (MA) in proteins exist as monomethyl-
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doi:10.1016/j.jasms.2008.11.008arginine (MMA), asymmetric dimethylarginine (aDMA),
or symmetric dimethylarginine (sDMA). Arg methyla-
tions frequently occur in eucaryotic cells in Arg-rich
domains, such as repetitive RGG-, RXR-, and DRG box
motifs [13–15].
Determination of the locations and types of MA
residues in proteins, and the quantification of methyl-
ation stoichiometries, is essential to understand the
regulatory, physiological, and pathological functions
associated with protein methylation. Conventional
methods for the detection and characterization of MA
residues include the incorporation of radioactive
methyl groups, amino acid analysis, and Edman se-
quencing [16–18]. Shortcomings of these methods in-
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residues are methylated, the necessity for laborious
separation, or very low analytical throughput [19].
Identification of MA residues by matrix-assisted laser
desorption/ionization time of flight (MALDI-TOF)
mass spectrometry, using either MS or MS/MS analy-
sis, has been reported [19–21]. However, methods
based upon MALDI-TOF cannot be applied to complex
samples, and may require prior knowledge of the target
MA protein/peptide.
Alternatively, liquid chromatography coupled to
electrospray ionization tandem mass spectrometry
(LC/ESI-MS/MS), which employs collision induced
dissociation (CID) for peptide fragmentation, has been
used to achieve peptide separation and identification of
MA residues in relatively complex samples such as
protein digest mixtures [21–26]. However, analysis of
MA-peptides by MS/MS-based approaches employing
ESI for ionization and CID for fragmentation can be
challenging for several reasons. First, Arg methylations
often occur in domains of multiple Arg residues in close
proximity that contain adjacent Arg box motifs [13–15].
Because trypsin seldom cleaves at the C-terminus of
MA residues [19,27], tryptic digestion of MA proteins
often results in peptides containing multiple internal
MA residues. Second, MA residues are rather basic, and
thus amenable to protonation in the gas phase. As a
result, MA peptides are usually highly charged under
ESI conditions (3 charges), and often provide only
limited sequence-informative b and y ions during CID
[28], perhaps because the positively charged internal
MA impedes the mobile proton on the peptide back-
bone [29]. This lack of sequence-informative ions ren-
ders it difficult to sequence MA-rich peptides or to
localize the methylated Arg residues by CID. Third, MA
moieties in peptides, particularly dimethylarginine
(DMA) residues, are labile under CID conditions. Thus
neutral losses such as dimethylamine (dma), dimethyl-
carbodiimide (dmc), or monomethylamine (mma) pre-
dominate over peptide backbone fragmentation. As a
result, CID spectra tend to be dominated by a few
fragments resulting from neutral losses and contain
few sequence-informative ions [22, 23], and informa-
tion on peptide sequence and methylation position
cannot be obtained (cf. Figure 3). It was observed
previously that CID of the multiply-charged MA
peptide VAAR*GR*GR*GMGR*GK (where *  DMA)
produced spectra consisting predominantly of several
ions resulting from neutral loss and containing very few
b and y ions [23]. Other studies showed similar trends
for peptides containing multiple MA residues when
fragmented by CID [30]. Finally, recent studies suggest
that Arg methylation may parallel phosphorylation in
its level of complexity, in terms of the locations at which
methylations can occur, and the possible stoichiometries
at each location [13]. This complexity further compounds
the difficulties in the analysis of MA peptides.
The technical challenges described above may ex-
plain why few studies describe the analysis of sequence,localization, and characterization of MA-peptides by
ESI-MS/MS, despite the biological importance of Arg
methylations. Therefore, a robust method for accurate
localization of MA residues and quantification of meth-
ylation stoichiometries in Arg-rich peptides would rep-
resent a significant analytical advancement that could
lead to new biological insights into the mechanisms of
protein methylation and its significance in biological
and pathological processes.
Here we describe the development of an analytical
approach based on LC/ESI-MS that provides improved
identification and characterization of MA-containing
peptides within Arg-rich domains. Our approach was
to employ electron-transfer dissociation (ETD), which is
a fragmentation technology developed recently by
Hunt and Coon [31], to identify highly-charged, Arg-
rich methylated peptides and to localize the sites of
methylation. ETD converts multiply charged peptide
cations into radicals through reaction with radical gas-
eous anions (e.g., fluoranthene) via an electron-transfer
process. The peptide cation radicals then undergo frag-
mentation of the N–C bond as a result of their poor
stability [32–35]. The resulting fragment ions that con-
tain the N- and C termini of the peptides are termed c
and z ions, respectively. Although ETD usually does
not fragment doubly charged peptide ions efficiently, it
does provide fairly uniform cleavage of peptide precur-
sors of higher charge states (3) [31, 36]. A recent study
by Coon and coworkers suggested that the fragmenta-
tion efficiency and resulting sequence coverage by ETD
is approximately proportional to the charge density
(i.e., number of charges/number of residues) of the
precursor peptide ions [28]. Because Arg methylations
frequently occur in Arg-rich domains that contain mul-
tiple closely-spaced Arg residues, it could be expected
that both the charge states and charge densities of such
peptide ions would be high under ESI conditions; this
should provide optimal peptide backbone fragmenta-
tion under ETD. Moreover, ETD is particularly well
suited for the characterization of peptides containing
labile modifications, because ETD often leaves them
intact during peptide bond dissociation [33, 37]. Pres-
ervation of methylation moieties during peptide bond
dissociation would provide abundant information on
the location of the modification.
The experimental system employed a biologically-
relevant Arg-rich peptide, denoted GAR (glycine- and
arginine-rich peptide) [38] (GRGGFGGRGGFRGGRGG),
which was synthesized both with and without specific
MA modifications, or subjected to methylation by in
vitro enzymatic methylation systems. The GAR pep-
tide comprises residues 679-695 of human nucleolin
(NP_005372), which is one of the most abundant nucle-
olar proteins of vertebrate cells. Nucleolin is involved in
biological processes such as ribosome biogenesis, tran-
scription, embryogenesis, and cell proliferation and
growth, as well as in pathological conditions such as
specific systemic autoimmune disorders [4]. Methyl-
ation of the GAR domain is essential for the function
509J Am Soc Mass Spectrom 2009, 20, 507–519 CID/ETD AND ORBITRAP FOR METHYLARGININE ANALYSISand localization of nucleolin [39], and is the target of a
potent pseudopeptide inhibitor of both HIV entry [40]
and cancer [41]. The methylation motifs contained in the
GAR peptide are common to many naturally occurring
methylated proteins [13–15]. Furthermore, despite the
important biological and pathophysiological significance
of Arg methylations as a family of post-translational
regulatory modifications, methylation patterns generated
by prevalent enzymatic systems such as the protein argi-
nine N-methyltransferases (PRMTs) are not well charac-
terized. Two PRMTs, PRMT1 and PRMT7, were em-
ployed to investigate the patterns of peptide methylation
produced enzymatically.
In terms of the experimental approach, ETD was
used to sequence the methylated GAR peptides and to
determine the positions of methylations. CID fragmen-
tation was used to characterize the type of MA deriva-
tization (i.e., MMA, sDMA, or aDMA). To ensure high-
confidence identification, an Orbitrap analyzer, which
provides high accuracy/resolution for the measure-
ment of m/z [42–44], was used to obtain accurate m/z
determinations of the peptide precursor ions and CID
fragment ions, as well as to perform relative quanti-
fication of the stoichiometries of the enzymatically-
methylated peptides.
Experimental
Materials
HPLC grade methanol, acetonitrile, and water were
from B and J (Muskegon, MI). Formic acid was from
Fluka (Buchs, Switzerland). Phenylmethanesulfonyl
fluoride (PMSF), benzamidine, and S-adenosylmethi-
onine were obtained from Sigma (St. Louis, MO). Caf-
feine, MAFA peptide, and Ultramark for Orbitrap cali-
bration were from Thermo Scientific (San Jose, CA).
Microcon centrifugal filters were obtained from Mil-
lipore (Billerica, MA). Two synthetic MA-rich pep-
tides, the unmodified GAR peptide (GRGGFGGR-
GGFRGGRGG) and the per-aDMA GAR peptide
(GR#GGFGGR#GGFR#GGR#GG, where #  aDMA),
were synthesized by the laboratory of Sandor Pongor
(International Center for Genetic Engineering and Bio-
technology, Trieste, Italy). The amino acid sequence of
the GAR peptide corresponds to the residues 679-695 of
human nucleolin (NP_005372). The C-termini of both
peptides were amidated.
In Vitro Methylation of the GAR Peptide by
PRMT1 and PRMT7
Two protein arginine methyltransferases, PRMT1 and
PRMT7, were employed to produce MA-peptides in
vitro using the unmodified GAR peptide as the sub-
strate. Both enzymes are recombinant GST-fusion pro-
teins; PRMT1 was the same enzyme preparation used in
a previous work [7] and PRMT7 was generously pro-
vided by Drs. Laurie Read and John Fisk (Departmentof Microbiology, University at Buffalo School of Medi-
cine). The unmodified GAR peptide was dissolved in
water at a concentration of 80 g/mL. Either 10 g/mL
PRMT1 or 4.3 g/mL PRMT7 was added along with 65
mM Tris (pH 8), 1 mM PMSF, 10 M benzamidine, and
100 M S-adenosylmethionine. The mixtures were then
incubated for 20 h at 23 °C. The reaction solutions were
loaded onto Microcon centrifugal membrane (30 kDa
MWCO) filter assemblies to remove the enzymes from
the peptides. Following 10 min of centrifugation at
12,000 g, 85% of the reaction solution containing
MA-peptides was recovered as filtrate.
Nano-LC/MS Analysis and Identification of
MA-Peptides
A nano-LC system consisting of a Spark Endurance au-
tosampler (Emmen, Holland) and four Eksigent direct-
flow capillary/nano LC pumps (Dublin, CA) that were
powered by pressurized nitrogen (100 p.s.i) were used
for the separation of MA-peptides. The nano-LC flow
path was lab-made and included a Vici 10-port low-
dead-volume valve (Houston, TX). A lab-made dy-
namic flow nano-spray interface was used to couple the
nano-LC system to a Thermo Scientific LTQ/ETD or to
a LTQ/Orbitrap (San Jose, CA).
Mobile phase A consisted of 0.1% formic acid in 2%
acetonitrile and mobile phase B was 0.1% formic acid in
84% acetonitrile. For analysis, MA-peptides were
loaded onto the reversed-phase (RP) peptide trap (5
mm  300 m I.D., Agilent, Palo Alto, CA) at a flow
rate of 10 L/min and then washed with mobile phase
A for 3 min. The trap was then switched online, and a
lab-packed reversed-phase nano C-18 column was em-
ployed for separation. The column consisted of 3 m
reversed-phase particles packed in a 25 cm long, 360
m o.d. and 75 m i.d. fused silica capillary terminated
with a noncoated tapered tip of 2 to 3 m diameter. The
flow rate was 250 nL/min and the gradient consisted of:
(1) a linear increase from 0% to 7% B over 5 min; (2) an
increase from 7% to 19% B over 55 min; (3) an increase
from 19% to 90% B in 1 min, and finally (4) isocratic at
90% B for 10 min.
For LTQ/ETD, theMSwasworking in data-dependent
mode; one scan cycle was comprised of an MS1 scan
(m/z range from 300 to 2000 with a target value of 3 
104) followed by six sequential dependent MS2 scans
(the target value was 1  104 and the maximum
injection time was 250 ms). The first, third, and fifth
MS2 scans were CID fragmentations of the first, second,
and third most-abundant precursors, respectively, pre-
senting in the MS1 spectrum. The second, fourth, and
sixth MS2 scans were ETD fragmentations correspond-
ing to the same group of precursors. For CID, the
activation time was 30 ms, the isolation width was 1.5 u,
the normalized activation energy was 35%, and the
activation q was 0.25. For ETD, a mixture of ultrapure
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99.995%) was used as the reaction gas. To obtain effi-
cient fragmentation, a high target value for fluoran-
thene anions (2  106) was used; the ETD reaction time
was set at 120 ms and the isolation width was 2 u;
supplemental activation, which uses a short CID acti-
vation process to dissociate the charge-stripped precur-
sors, was employed to enhance the fragmentation effi-
ciency for doubly-charged precursors. For Orbitrap
analysis, one scan cycle included an MS1 scan (m/z
300–2000) at a resolution of 100,000 followed by three
MS2 scans (resolution at 30,000) to fragment the three
most abundant precursors found in the MS1 spectrum.
The target values for MS1 and MS2 by Orbitrap were,
respectively, 2  106 and 2  105. To ensure mass
accuracy, the Orbitrap analyzer was calibrated on the
same days that the experiments were performed. For
both LTQ/ETD and Orbitrap experiments, dynamic
exclusion was used with one repeat counts, 35 s repeat
duration, and 100 s exclusion duration.
We employed an offline precursor matching ap-
proach to obtain accurate m/z and charge states of the
MA-peptides putatively identified by LTQ/ETD. The
same sample was analyzed by nano-LC/LTQ/Orbitrap
immediately following the nano-LC/LTQ/ETD analy-
sis, using the same chromatographic system, gradient
conditions, and nano-spray interface. The precursor m/z
and retention times of the peptides that were putatively
identified using LTQ/ETD were matched against data
from the LTQ/Orbitrap, using an m/z window thresh-
old of 0.5 u and a retention time window threshold of
0.2 min. Owing to the excellent run-to-run reproducibil-
ity of the nano-LC system, the matches were facile.
Spectra generated by ETD were processed using
BioWorks software (3.3.1, Thermo Scientific), which
incorporates the SEQUEST algorithm, to find the best
matching sequences. Briefly, the charge states of the
precursors of ETD spectra were assigned by the
Charger program (Thermo Scientific) and then searched
against a database containing the sequence of the GAR
peptide. Differential modifications of MMA (14.0156
Da) and DMA (28.0313 Da) on Arg residues, and a
static modification of C-terminal amidation (0.9840
Da) were considered. Mass tolerances were 1.4 and
1.0 u, respectively for the precursor and fragments. The
resulting identifications were first filtered using the
scores of Xcorr (Cross-correlation score; 2 precursor
2.5, 3  3.2, 4  3.8) and then using the Sf scores
(final score,  0.8). In cases where more than one
methylation pattern resulted for one ETD spectrum,
final confirmation of the most probable assignment was
obtained by manual inspection of the spectrum for c
and z ions. For putatively identified MA-peptides, the
charge states and accurate m/z of precursors were
obtained by the Orbitrap, and any identification with
incorrect charge state assignment or precursor mass
error larger than 10 ppm was eliminated.Relative Quantification of MA-Peptides
To calculate the stoichiometries of the MA-peptides
produced by the in vitro methylation systems, the
extracting ion currents (XIC) of the precursors obtained
by the Orbitrap were utilized for relative quantification.
For each identified MA-peptide, the XICs were ex-
tracted in a narrow m/z window (0.01 u) around the
monoisotopic m/z for each available charge state. The
area-under-curve (AUC) for each precursor at each
charge state was calculated using Qualbrowser
(Thermo Scientific). The relative abundance (RA) of a
MA-peptide (peptide A) was calculated using the fol-
lowing formula:
RA of Peptide A

The sum of the AUCs of peptide
A under all available charge states
The sum of the AUCs under all charge
states of all identified peptides in the sample
 100%
Results and Discussion
Ionization and Fragmentation Behaviors of
Methylated and Nonmethylated Arg-Rich
GAR Peptides
We and others have shown that the CID reactivity,
fragmentation behavior, and the amount of obtainable
sequence-informative product ions of a peptide ion are
heavily dependent upon the charge state of the target
peptide [29, 45–47]. Therefore, it was essential to inves-
tigate the ionization behavior of MA-rich peptides
before studying fragmentation. The GAR-domain pep-
tide of nucleolin, which contains prevalent Arg-rich
consensus domains that are methylated in biological
systems, was synthesized both in unmodified form and
with asymmetric dimethylations (aDMA) on all Arg
residues (per-aDMA GAR). Using ESI and an Orbitrap
analyzer, the charge state distribution for both peptides
was determined readily (Figure 1). The unmodified
GAR peptide was predominantly quadruply-charged,
with much less abundant double-, triple-, and quintuple-
charge state ions (Figure 1a). Because MA residues
would be considered less basic than unmodified Arg
residues in biochemical processes [13], it might be
expected that the charge state distribution of the per-
aDMA GAR peptide would shift toward lower charge
states. However, it was observed that the per-aDMA
GAR peptide exhibited a charge state distribution al-
most identical to its unmodified cognate (Figure 1b),
suggesting that MA residues possess affinity for pro-
tons similar to unmodified Arg residues during the ESI
process.
To characterize the fragmentation behavior of the
unmodified- and per-aDMA GAR peptides, both were
subjected to CID and ETD activation. The CID spectrum
of the predominant, quadruply-charged unmodified
GAR peptide yielded a number of fragments arising
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and fragments produced via other undesirable path-
ways (Figure 2a). However, very few sequence-
informative b and y ions were observed. This observa-
tion can be explained by the “mobile proton” model [29,
48]: for effective peptide backbone cleavage under CID
conditions, an ionizing proton must be transferred to
positions along the length of the peptide, weakening the
amide bond at those positions and facilitating their
cleavage. According to this model, the multiple fixed
protons localized on the internal Arg residues of the
highly-charged GAR peptide would impede the move-
ment of the mobile proton, thus preventing uniform
cleavage of the peptide backbone, which is necessary to
obtain abundant sequence information.
Similarly, the CID of the quadruply-charged per-
aDMA GAR peptide also produced a limited number of
b and y ions. Moreover, because the MA moieties are
labile during CID process, the CID spectrum was dom-
inated by a fragment corresponding to a facile cleavage
of dma from the precursor (Figure 2c). Due to the
limited sequence information provided by these spec-
tra, sequencing by SEQUEST did not result in any
identification. Clearly, CID was not suitable for se-
Figure 1. The charge state distributions of the GAR peptides under
positive ESI, as obtained using an Orbitrap analyzer. (a) The MS1
spectrum of the unmodified peptide GRGGFGGRGGFRGGRGG;
(b) the MS1 spectrum of the per-aDMA peptide GR#GGFGGR#
GGFR#GGR#GG, where #  aDMA. Abbreviations: z, charge
state; R, resolution.quencing these highly-charged MA-peptides.In contrast, ETD provided uniform dissociations of
the peptide backbone of the same precursors and
provided highly abundant sequence information.
Nearly-complete c and z ion ladders were obtained
for both the unmodified and per-aDMA GAR pep-
tides (Figure 2b and d), enabling highly confident
sequencing of the peptides, as expressed by the high
scores of Xcorr and Sf achieved. Because ETD is not
sensitive to side-chain chemistry, cleavage of the
labile methylation moieties was not observed in the
product ion spectrum of the per-aDMA GAR peptide,
and the methyl moieties were well-preserved on c
and z ions (Figure 2d). Clearly, ETD is an ideal
technique for the analysis of MA- and Arg- rich
peptides, as neither the high charge states nor the
labile methylations limited the production of abun-
dant sequence information.
It can be observed from Figure 1 that doubly- (2)
and triply- (3) charged ions were also generated
during ESI, although at very low abundance (2% and
10% of the intensity of the 4 species, respectively).
Because CID can often produce relatively abundant
sequence information for doubly- and triply-charged
peptides [29, 48], it may be possible to use CID to
sequence MA-rich peptides, provided the concentration
of these peptides is sufficiently high in the sample so
that the 2 or 3 precursors have the necessary abun-
dance to provide a reasonable yield of fragments. To
test this possibility, we investigated the CID fragmen-
tation behavior of the 2 and 3 precursors of per-
aDMA GAR using a peptide solution of high concen-
tration (80 g/mL). Nevertheless, surprisingly little
sequence information was obtained; the CID spectra for
both charge states were dominated by ion(s) corre-
sponding to neutral losses of methylation moieties, and
limited numbers and low abundances of b and y ions
(Figure 2e and g). SEQUEST identification using these
spectra yielded very poor Xcorr scores (0.7 and 0.16 for
3 and 2 charged precursors, respectively), which
were far below prevailing criteria for confidence (e.g.,
Xcorr  2.0 for 2 and  2.5 for 3). There are several
possible explanations for this observation. First, be-
cause of the lability of the MA moieties, CID may
promote initial elimination of the methylation moiety,
thus largely precluding further fragmentation of the
peptide backbone. Second, the peptide contains four
internal MA residues, which are highly basic in the gas
phase, as discussed above. As a result, the two (for the
2 precursor) or three (for the 3 precursor) ionizing
protons are most likely localized on the MA residues,
rather than on the less basic N-terminus. According to
the “mobile proton” model, a mobile proton associated
with the N-terminus is essential for even peptide back-
bone cleavage [29, 48], and the lack of mobile proton on
these 2 and 3 precursors would result in a very
limited number of sequence-informative b and y ions in
the CID spectra.
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3 precursors produced significantly more sequence
information (Figure 2f and h). Interestingly, ETD of the
2 precursor showed mostly “long” c and z ions (i.e.,
fragments containing more than half of the total resi-
dues of the peptide) rather than a complete set of both
ions (Figure 2h). Because the 2 precursor was charge-
reduced in the ETD process, and one precursor ion
cannot dissociate into both c and z ions when only one
net positive charge is available, the number of c and z
ion species obtained from a 2 precursor is signifi-
cantly less than the number obtained from more highly
charged precursors. Nevertheless, the fragments in Fig-
ure 2h represent 11 inter-residue cleavages out of a total
of 16 inter-residue bonds in the peptide, which pro-
vided satisfactory sequence coverage and consequently
Figure 2. Representative CID and ETD spectra
per-aDMA GAR peptides (GR#GGFGGR#GGFR
different charge states. (a) CID of the quadrupl
quadruply-charged unmodified GAR peptide;
peptide; (d) ETD of the quadruply-charged per
per-aDMA GAR peptide; (f) ETD of the tri
doubly-charged per-aDMA GAR peptide; (h) E
CID did not result in any confident identificatio
precursors. Abbreviations: Xcorr, cross-correlati
confident identification was Xcorr 2 if z 2, Xc
was also required.a highly confident identification (Xcorr  3.14 and Sf 0.87). As a result of the use of supplemental activation,
as well as a high anion intensity for ETD (cf. the
Experimental section), ETD fragmentation efficiency for
the 2 precursor was fairly high (Figure 2h) and thus
probably contributed to the high SEQUEST peptide
scores obtained.
Confident Determination of Methylation Patterns
and Relative Quantification of the Stoichiometries
of Methylarginines on MA-GAR Peptides
Produced In Vitro by Enzymatic Methylation
The majority of Arg methylations in eucaryotic cells
appear to be performed by members of the protein
arginine N-methyltransferase (PRMT) family [13]. Spe-
e unmodified (GRGGFGGRGGFRGGRGG) and
R#GG, where #  aDMA) using precursors of
rged unmodified GAR peptide; (b) ETD of the
ID of the quadruply-charged per-aDMA GAR
A GAR peptide; (e) CID of the triply-charged
arged per-aDMA GAR peptide; (g) CID of
f the doubly-charged per-aDMA GAR peptide.
the GAR peptides, even with low-charge-state
ore; Sf, final score (ETD only). The criteria for a
2.8 if z 3, Xcorr 4 if z 4; for ETD, Sf 0.8of th
#GG
y-cha
(c) C
-aDM
ply-ch
TD o
n for
on sc
orrcific PRMT enzymes could be selective for particular
data.
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ation patterns [4, 13]. Therefore, determination of the
types and positions of methylations produced by these
enzymes on common Arg-rich motifs, such as are
present in the GAR peptide, is essential to understand
their mechanisms of action and role in Arg methylation
in biological systems. To date, there exists no reliable
method for the identification and characterization of
these enzymatically-produced methylations, largely as
a result of the inability of CID to analyze Arg-rich
peptides, as demonstrated above. Furthermore, given
the perplexing position preference of enzymatic meth-
ylation [13], determination of the exact localization of
each methylation among closely spaced Arg residues is
clearly very challenging. As demonstrated with the
synthesized per-aDMA GAR peptide (above), ETD was
able to provide a nearly complete ladder of c and z ions,
and also preserved the labile Arg methylations of
highly-charged precursors, which is essential for accu-
rate localization of MA residues. Therefore, ETD was
investigated for the analysis of enzymatically methyl-
ated GAR peptides.
The products of two representative in vitro enzy-
matic methylation systems, employing PRMT1 and
PRMT7, were analyzed using nano-LC coupled with
ETD fragmentation and Orbitrap analysis. Although it
would be possible to conduct the analysis by direct
infusion of the reaction mixtures into the MS system,
nano-LC was employed to eliminate the possible effects
of sample buffers and reaction reagents on the ioniza-
tion of the MA-peptides. Furthermore, because there
are four Arg residues in the peptide, isomeric MA-
peptides may be produced that have the same mass
adduction (by MA) but are methylated at different
Figure 3. Representative MS spectra for the ide
methylation systems. (a) ETD spectrum of a
GRGGFRGGRGG, where #  aDMA; the symmet
confirmation of the identification of the peptid
measurement using the Orbitrap; (c) ETD spe
GR*GGFGGR*GGFRGGR*GG, where *  MMA;
GR*GGFGGR*GGFRGGR*GG using the Orbitrappositions. Chromatographic resolution of these isomerswas essential for the identification and localization MA
positions on these peptides (cf. Figure 4).
Determination of the Types and Locations of Arg
Methylations on Enzymatically Produced
MA-GAR Peptides
As observed with the synthesized methylated peptides
(above), GAR peptides methylated by both enzymatic
systems were also predominantly quadruply-charged
under positive ESI (spectra not shown). ETD fragmen-
tation of these ions produced nearly complete ladders
of complementary c and z ions, and thus enabled highly
confident peptide identification, as well as accurate
localization of the MA-residues. In those cases in which
not all Arg residues were methylated, localization of the
methylations by SEQUEST was confounded because of
the close proximity of the four Arg residues in the GAR
peptide. In fact, SEQUEST often provided several pos-
sible assignments of methylation patterns from a single
ETD spectrum, with some of the assignments having
similar scores. In such cases, manual examination of the
c and z ions was necessary to determine the specific
modification sites, and the MA-peptides tentatively
identified by ETD were examined further using high
accuracy precursor measurements.
For proteomic research employing MS, high mass
accuracy measurement of peptide precursor ions assists
considerably in the elimination of non-obvious false
positives [49]. Therefore, a high-resolution/accuracy
Orbitrap analyzer [42–44] was used to measure the m/z
of precursor ions of the MA-peptides identified by ETD.
Because an integrated Orbitrap-ETD instrument was
cation of the MA-peptides produced by in vitro
T1-produced peptide identified as GR#GGFG
the DMA was determined separately by CID; (b)
#GGFGGRGGFRGGRGG by accurate precursor
of a PRMT7-produced peptide identified as
nfirmation of the identification of the peptide as
Abbreviation: , mass error in ppm.ntifi
PRM
ry of
e GR
ctrum
(d) conot available, samples were analyzed sequentially on
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precursor matching was employed (Experimental sec-
tion). Because of the excellent run-to-run reproducibil-
ity of the nano-LC system, offline matches were facile
(chromatograms not shown). The accurate m/z and
charge state information obtained for the putative MA-
peptides using the Orbitrap was used to filter MA-
peptides in the ETD data; any identification in which
the precursor had incorrect charge state assignments or
the mass error was greater than 10 ppm was considered
a false positive identification.
It was observed that PRMT1 and PRMT7 produced
various patterns of GAR peptide methylations. Under
the reaction conditions used here, the major methyl-
ation type catalyzed by both enzymes was MMA, but
lower abundance DMA products were also produced
(Table 1). Integration of the high-accuracym/z data from
the Orbitrap with the ETD data reduced considerably
the number of putative identifications; of the 17 MA-
peptides provisionally identified by ETD, five were
eliminated because the precursors did not fall within
the 10 ppm mass error criteria. It is important to note
that all of these false-positive identifications had high
Figure 4. Typical ETD spectra and chromatogram for unambigu-
ous identification of isomeric MA-peptides. (a) XIC extracted within
the narrow m/z range of 405.71-405.73; the vertical dashed lines
denote the timeswhen ETD fragmentationswere performed. (b) ETD
spectrum acquired at the time of ETD-I, which enabled the identifi-
cation of the earlier-eluting isomer as GR@GGFGGRGGFRGGR@GG
(where @  sDMA; the symmetry of the DMA was determined in
parallel by CID); (c) ETD spectrum acquired at the time of ETD-II,
which identified the later-eluting isomer as GR@GGFGGRGGFR*
GGR*GG (where *  MMA).scores. This finding emphasizes the importance ofhighly accurate measurement of the m/z of precursor
ions to eliminate false-positive identifications that oth-
erwise appear acceptable. All peptide identifications
that passed the acceptance criteria are shown in Table 1.
To investigate whether some MA-peptides were gen-
erated via sample preparation artifacts, as previously
reported by Qin and coworkers [24], we also analyzed
negative control samples in which the GAR peptide was
incubated in the reaction mixture lacking enzyme. No
MA-peptides were identified in the negative control
samples (data not shown).
ETD spectra used for the identification of two repre-
sentative MA-peptides, one dimethylated by PRMT1
and the other monomethylated by PRMT7, are shown
in Figure 3a and c. Accurate m/z- and charge state
information obtained with the Orbitrap confirmed the
identifications (Figure 3b and d). Not surprisingly, CID
provided very poor sequence information for these
MA-peptides, for the reasons discussed above (spectra
not shown).
Sufficient chromatographic separation was found to
be essential for the identification of isomeric MA-
peptides, which are expected to occur fairly frequently by
enzymatic methylation within domains rich in closely-
spaced Arg residues. Isomeric MA peptides possess the
same peptide backbone and m/z, but differ in the
position of the methylations; the polarity of such iso-
meric MA-peptides is close, and therefore they elute
chromatographically in close proximity. If isomeric
peptides were not separated, the ETD spectra would
contain mixed c and z ions from multiple isomers,
which could result in incorrect localization, low match-
ing scores, or even a failure of identification, as we
observed in preliminary experiments (not shown).
Therefore, we optimized a shallow gradient separation
procedure to resolve isomeric peptides (cf. Experimen-
tal section). Figure 4 shows an example in which the
combination of sufficient nano-LC separation and ETD
fragmentation enabled unambiguous identification of
isomeric MA peptides produced enzymatically by
PRMT7. Two quadruply-charged isomers, having an
observed m/z of 405.723, were resolved (Figure 4a). ETD
fragmentation performed within each of the retention
time windows of the two isomers provided nearly-
complete ladders of sequence-informative fragments
and thus enabled accurate determination of the types
and positions of methylations on both (Figure 4b and c).
The presence of dimethylated z3-z15 and c3-c14 (Figure
4b), and the fact that both c15 and z16 carry two
dimethyl groups, clearly indicates that the MA-peptide
that eluted at 13.0 min is dimethylated on the two Arg
residues closest to the C- and N-termini. Dimethylated
c2-c4 ions and monomethylated z3-z8 ions were ob-
served for the peptide that eluted at 14.2 min. In
addition, z11 and z13 carry two MMA, and c9-c13 carry
one MMA and one DMA. These observations permitted
the locations of the methylations to be determined
unambiguously, as shown in Figure 4c. The DMA
al m/z
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as sDMA residues by CID, as described below.
Identification of Methylation Types Via
Characteristic Neutral Losses Under CID
Combined with High-Resolution Product Ion Scan
The ability to identify different types of methylations,
and particularly the discrimination of aDMA and
sDMA, is important because of reported differences in
biological actions [15, 23]. Because the methylation
moieties were observed to remain intact during ETD
fragmentation, it is not feasible to differentiate aDMA
and sDMA by ETD. However, although CID was not
suitable for the sequencing of Arg-rich MA-peptides,
previous studies demonstrated that peptides containing
different types of methylations produced characteristic
and specific neutral loss fragments [19, 22, 23], which
are summarized in Table 2. Previous assignments of the
characteristic neutral losses of MA-peptides were per-
formed with low-resolution/accuracy MS analyzers
such as ion traps and quadrupoles. The use of an
Orbitrap analyzer for this task is advantageous because
the accurate m/z and charge state information provided
would not only enable a highly confident examination/
confirmation of these proposed neutral loss species, but
also would aid in the interpretation of fragment spectra.
Therefore, the Orbitrap was employed to perform a
close inspection of the CID fragmentation spectra of
MA-GAR-peptides. Representative spectra are shown
in Figure 5. For the synthesized per-aDMA peptide, the
Table 1. aNano-LC/CID/ETD-Orbitrap identification and relati
produced by in vitro methylation
Sequence m/z (4) bRe
Standard peptides
GRGGFGGRGGFRGGRGG 391.709
eGR#GGFGGR#GGFR#GGR#GG 419.739
Methylation products of PRMT7
GRGGFGGRGGFRGGRGG 391.709
GRGGFGGRGGFRGGR*GG 395.212
GR*GGFGGRGGFRGGR*GG 398.715
GR@GGFGGRGGFRGGR@GG 405.725
GR@GGFGGRGGFR*GGR*GG 405.722
GRGGFGGRGGFR*GGR*GG 398.717
GR*GGFGGR*GGFRGGR*GG 402.220
Methylation products of PRMT1
GRGGFGGRGGFRGGRGG 391.709
GR#GGFGGR#GGFR#GGR#GG 419.739
GR#GGFGGRGGFRGGRGG 398.714
GR*GGFGGRGGFR*GGRGG 398.715
GR*GGFGGR*GGFRGGRGG 398.715
GRGGFGGR*GGFRGGRGG 395.212
GR*GGFGGRGGFRGGRGG 395.211
aA synthesized peptide corresponding to residues 679-695 of human nu
bThe relative abundance of each peptide was normalized against the t
cThe Sf and Xcorr are two scores that evaluate the confidence of SEQU
z4 were considered high confidence.
dThe mass error for the precursor ions (observed m/z versus theoretic
e#  aDMA, @  sDMA and *  MMA.most abundant fragments were confirmed to resultfrom neutral loss of dma and dmg, with less than 5 ppm
mass error (Figure 5a). For a MA-GAR peptide pro-
duced enzymatically by PRMT7, the CID spectrum
contained fragments characteristic of both sDMA and
MMA, but not aDMA, suggesting that the DMA near
the N-terminus is an sDMA (Figure 5b). In Figure 5c,
the presence of high-abundance neutral losses of mmg
and mma indicates that the MA-peptide contains only
MMA, which agrees with the ETD results (Figure 3c).
CID of MA-peptides not only permits discrimination
of sDMA versus aDMA, but also may aid sequencing by
providing information supplementary to that obtained
by ETD. For example, in the event that the c and z ions
obtained from an Arg-rich peptide are insufficient to
discriminate between the alternative possibilities of
(1) MMA on two Arg residues in close proximity, or
(2) DMA on a single Arg residue, the type-specific
neutral losses obtainable with CID would eliminate this
antification of methylarginine residues on a nucleolin peptide
abundance (%) cSf/Xcorr dMass error (ppm)
— 0.98/6.51 0.25
— 0.98/5.99 0.02
1.0 0.97/6.05 1.50
12.6 0.98/6.55 0.02
25.1 0.98/6.77 1.69
0.4 0.98/5.44 2.58
0.3 0.98/6.03 4.16
4.5 0.98/5.93 2.35
56.1 0.98/6.55 0.28
85.2 0.98/6.32 1.91
2.1 0.98/5.4 0.81
2.5 0.97/5.29 4.16
1.3 0.98/5.63 2.50
1.2 0.98/5.66 2.39
2.1 0.98/5.82 0.48
5.6 0.98/6.44 2.15
n (NP_005372), was used as the substrate for both PRMT1 and PRMT7.
ummed abundance of peptides in the sample.
identification of an ETD spectrum. Values of Sf0.80 and Xcorr 4 for
) measured by Orbitrap.
Table 2. Summary of characteristic CID neutral losses from
different types of methylarginines as proposed by previous
studies [19, 22, 23]
Neutral loss
aMass
(Da)
bMethylation
type
Dimethylamine (dma) 45.058 aDMA
Dimethylguanidine (dmg) 87.087 aDMA or sDMA
Dimethylcarbodiimide (dmc) 70.053 sDMA
Monomethylamine (mma) 31.042 MMA or sDMA
Monomethylguanidine (mmg) 73.064 MMA
aThe values are all for monoisotopic mass.
bve qu
lative
cleoli
otal s
ESTAbbreviations: aDMA  asymmetric dimethylarginine; sDMA  sym-
metric dimethylarginine; MMA  monomethylarginine.
 mo
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useful if the abundance of the MA-peptide was rela-
tively low, which is frequently the case for many
biological samples. Under such conditions, ETD may
not be able to produce a sufficiently complete sequence
ladder.
It is interesting to note that the types of methylation
products produced by PRMT7 have been debated pre-
viously; Miranda et al. observed that PRMT7 produced
only MMA [50], whereas Lee and coworker showed
that PRMT7 catalyzed only the formation of sDMA [51].
Here we observed that PRMT7 produced both MMA
and sDMA on the GAR peptide (Table 1). As for
PRMT1, we observed that both MMA and aDMA were
generated. Relative quantification by Orbitrap analysis
revealed that the stoichiometry of these methylations
was significantly different for the two enzymes (Table 1
Figure 5. Typical high-resolution/accuracy CID
methylations, which were acquired by LTQ/O
GGR#GG (# aDMA); (b) CID spectrum of the PR
(where @  sDMA and *  MMA); (c) CID
GGR*GGFRGGR*GG. Abbreviations: dma  dime
ylcarbodiimide, mma  monomethylamine, mmgand below).Quantification of the Arg Methylation
Stoichiometry Produced by PRMT Enzymes
The stoichiometry of PRMT methylation products is of
interest for understanding the biological role of this
family of enzymes. Our strategy to quantify MA stoi-
chiometry was to utilize the precursor ion signals
measured by the Orbitrap analyzer, which provides a
wide dynamic range and high selectivity [52]. The AUC
of the extracting ion current (XIC) for all charge states of
a given MA-peptide were summed, and the relative
quantity of the MA-peptide was calculated as described
in the Experimental section. To ensure specificity, the
XICs were extracted within a narrow m/z window (0.02
amu). Table 1 shows the relative abundances calculated
for all identified MA-peptides generated enzymatically
by PRMT1 and PRMT7. The isomeric MA-peptides
ctra of GAR peptides bearing different types of
p. (a) CID spectrum of GR#GGFGGR#GGFR#
produced peptide GR@GGFGGRGGFR*GGR*GG
rum of the PRMT7-produced peptide GR*GGF
mine, dmg  dimethylguanidine, dmc  dimeth-
nomethylguanidine.spe
rbitra
MT7-
spect
thylalisted were all resolved chromatographically, and the
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the observation that the unmodified peptide substrate
represented only 1% of the total peptides in the PRMT7
reaction mixture but 85.2% of the PRMT1 reaction
mixture, it can be concluded that the PRMT7 used in
this study was significantly more efficient than PRMT1
in the in vitro system employed. Also, it can be ob-
served (Table 1) that for both enzymes, the majority of
the Arg methylation products are MMA. For PRMT7 in
particular, sDMA-peptides account for less than 1% of
the total MA-peptides produced, and the predominant
products bear MMA on two or three Arg residues.
It should be noted that this quantification approach
is based on the assumption that all forms of the GAR
peptide (methylated and nonmethylated) exhibit simi-
lar ionization efficiencies. This assumption appears to
be reasonable due to the observation that the ionization
efficiencies of the unmodified- and per-aDMA peptides
were very similar (cf. Figure 1). It is also important to
note that because one form of methylation at a specific
residue location often exists among different MA-
peptides, the calculated relative abundances are per
MA-peptide, but not necessarily per Arg residue posi-
tion. Finally, this quantification strategy may not be
readily adaptable in highly complex systems such as
tryptic digests of biological samples, where differential
ion suppression effects could compromise quantifica-
tion accuracy. To address this problem, it may be
feasible to incorporate internal standards for quantifi-
cation in biological samples, and this possibility will be
investigated in ongoing studies.
Conclusions
The confidence of peptide sequencing by database
searching relies heavily on the extent and quality of the
sequence information generated by MS/MS events [42].
Because of their intrinsically high charge states under
ESI and the lability of methyl moieties, the sequencing
of methylated Arg-rich peptides is difficult when CID is
used as the means of fragmentation. Although the
details of the dissociation mechanism by ETD have not
been elucidated fully, apparently ETD neither relies
upon the mobile protons to dissociate peptides, nor is
sensitive to side-chain chemistry [31, 36]. Employing
ETD fragmentation to investigate methylated Arg-rich
peptides that contain methylation motifs widely ob-
served in eucaryotic biological systems, the current
work demonstrated that ETD fragmentation produced
abundant sequence information for all available charge
states, and permitted highly confident sequencing and
accurate localization of methylations. CID, in contrast,
provided few sequence-informative fragments for these
peptides. However, CID can assist in the determination
of the types of methylations, and particularly in the
discrimination between aDMA and sDMA, as sug-
gested by previous work [19, 22, 23] and confirmed here
by the high-resolution/accuracy product ion scans pro-
duced by the LTQ/Orbitrap. Because of these comple-mentary capabilities, combining alternating ETD and
CID in a single run provided the data necessary for the
comprehensive identification of MA-peptides.
The extent to which this strategy will permit elucida-
tion of Arg methylation patterns in the non-arginine-rich
motifs that exist biologically remains to be determined.
However, missed tryptic cleavages at the C terminus of
MA is a well recognized phenomenon, and this pro-
duces peptide charge states  2. Furthermore, methy-
lations in other peptide motifs are likely to be labile
under CID, as was observed for the peptides investi-
gated here. Thus, there is confidence that the advan-
tages of ETD in this combined ETD/CID strategy will
provide the ability to elucidate methylation patterns in
a wider range of biologically-occurring motifs than
represented in the peptides analyzed here.
The products of two enzymatic methylation systems
were investigated as proof-of-principle for application of
this approach to biological systems. Following nano-LC
separation, the MA-peptides generated by PRMT1 and
PRMT7 were sequenced and the methylations were
localized using ETD. The types of methylations were
determined by using CID fragmentation that inter-
leaved with ETD in a single run. To confirm identifica-
tions, high-resolution/accuracy Orbitrap data were em-
ployed to eliminate false-positives. It was observed that
PRMT1 produced both MMA- and aDMA-peptides
with relatively low efficiency, as the majority of the
substrate was unmodified in the reaction system used
here. In contrast, the PRMT7 preparation used here
converted 85% of the substrate to MA-peptides, and
generated both MMA and sDMA. Relative quantifica-
tion of the stoichiometry of these products by Orbitrap
analysis revealed that the vast majority of the MA-
peptides produced by PRMT7 were MMA-peptides.
The approach developed here, employing nano-LC
separation, interleaved CID and ETD, and parallel
Orbitrap analysis, permitted facile sequencing, accurate
methylation localization, and relative quantification of
methylation stoichiometry for enzymatically-produced
peptides that contain biologically-relevant Arg-rich mo-
tifs. This capability will provide valuable insight into
the biological roles and mechanisms of action of these
enzymes. Furthermore, this strategy may be adapted to
the analysis of methylated proteins from biological
samples after digestion of target proteins with the
appropriate enzymes, which is currently on-going in
our lab.
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